{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,23]],"date-time":"2026-10-23T05:36:05Z","timestamp":1792733765029,"version":"4.5.0"},"reference-count":56,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2019,3,7]],"date-time":"2019-03-07T00:00:00Z","timestamp":1551916800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Immunol."],"DOI":"10.3389\/fimmu.2019.00305","type":"journal-article","created":{"date-parts":[[2019,3,7]],"date-time":"2019-03-07T06:30:17Z","timestamp":1551940217000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":76,"title":["Biomarkers for Diagnosis of Axial Spondyloarthritis, Disease Activity, Prognosis, and Prediction of Response to Therapy"],"prefix":"10.3389","volume":"10","author":[{"given":"Walter P.","family":"Maksymowych","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2019,3,7]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"2702","DOI":"10.1002\/art.39257","article-title":"A randomized, double-blind, placebo-controlled, sixteen-week study of subcutaneous golimumab in patients with active non-radiographic axial spondyloarthritis","volume":"67","author":"Sieper","year":"2015","journal-title":"Arthritis Rheumatol"},{"key":"B2","doi-asserted-by":"publisher","first-page":"2378","DOI":"10.1016\/S0140-6736(18)32463-2","article-title":"Efficacy and safety of filgotinib, a selective Janus kinase 1 inhibitor, in patients with active ankylosing spondylitis (TORTUGA): results from a randomised, placebo-controlled, phase 2 trial","volume":"392","author":"Van der Heijde","year":"2018","journal-title":"Lancet"},{"key":"B3","doi-asserted-by":"publisher","first-page":"2441","DOI":"10.1016\/S0140-6736(18)31946-9","article-title":"Ixekizumab, an interleukin-17A antagonist in the treatment of ankylosing spondylitis or radiographic axial spondyloarthritis in patients previously untreated with biological disease-modifying anti-rheumatic drugs (COAST-V): 16 week results of a phase 3 randomised, double-blind, active-controlled and placebo-controlled trial","volume":"392","author":"Van der Heijde","year":"2018","journal-title":"Lancet"},{"key":"B4","doi-asserted-by":"publisher","first-page":"361","DOI":"10.1002\/art.1780270401","article-title":"Evaluation of diagnostic criteria for ankylosing spondylitis. A proposal for modification of the New York criteria.","volume":"27","author":"van der Linden","year":"1984","journal-title":"Arthritis Rheumatol"},{"key":"B5","doi-asserted-by":"publisher","first-page":"1785","DOI":"10.3899\/jrheum.090346","article-title":"Reappraisal of OMERACT 8 draft validation criteria for a soluble biomarker reflecting structural damage endpoints in rheumatoid arthritis, psoriatic arthritis, and spondyloarthritis: the OMERACT 9 v2 criteria","volume":"36","author":"Maksymowych","year":"2009","journal-title":"J Rheumatol."},{"key":"B6","doi-asserted-by":"publisher","first-page":"1211","DOI":"10.1136\/annrheumdis-2012-202208","article-title":"Autoantibodies against CD74 in spondyloarthritis","volume":"73","author":"Baerlecken","year":"2014","journal-title":"Ann Rheum Dis."},{"key":"B7","doi-asserted-by":"publisher","first-page":"1079","DOI":"10.1136\/annrheumdis-2012-202177","article-title":"High prevalence of anti-CD74 antibodies specific for the HLA class II-associated invariant chain peptide (CLIP) in patients with axial spondyloarthritis","volume":"73","author":"Baraliakos","year":"2014","journal-title":"Ann Rheum Dis."},{"key":"B8","doi-asserted-by":"publisher","first-page":"38","DOI":"10.1186\/s13075-018-1535-x","article-title":"Anti-CD74 antibodies have no diagnostic value in early axial spondyloarthritis: data from the spondyloarthritis caught early (SPACE) cohort","volume":"20","author":"de Winter","year":"2018","journal-title":"Arthritis Res Ther."},{"key":"B9","doi-asserted-by":"publisher","DOI":"10.1002\/art.40777","article-title":"Sensitivity and specifity of autoantibodies against CD74 in axial spondyloarthritis","author":"Reichers","year":"2018","journal-title":"Arthritis Rheumatol."},{"key":"B10","doi-asserted-by":"publisher","first-page":"2793","DOI":"10.1002\/art.38763","article-title":"Role of protein phosphatase magnesium-dependent 1A and anti-protein phosphatase magnesium-dependent 1A autoantibodies in ankylosing spondylitis","volume":"66","author":"Kim","year":"2014","journal-title":"Arthritis Rheumatol"},{"key":"B11","doi-asserted-by":"publisher","first-page":"875","DOI":"10.1093\/hmg\/ddy008","article-title":"Circulating microRNAs as potential biomarkers of disease activity and structural damage in ankylosing spondylitis patients","volume":"27","author":"Perez-Sanchez","year":"2018","journal-title":"Hum Mol Genet"},{"key":"B12","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1080\/14397595.2018.1519103","article-title":"Serum calprotectin correlates with risk and disease severity of ankylosing spondylitis and its change during first month might predict favorable response to treatment","author":"Hu","year":"2018","journal-title":"Modern Rheumatol."},{"key":"B13","doi-asserted-by":"publisher","first-page":"21","DOI":"10.1186\/s13075-017-1223-2","article-title":"A longitudinal study of fecal calprotectin and the development of inflammatory bowel disease in ankylosing spondylitis","volume":"19","author":"Klingberg1","year":"2017","journal-title":"Arthritis Res Ther."},{"key":"B14","doi-asserted-by":"publisher","first-page":"1357","DOI":"10.1136\/annrheumdis-2015-208025","article-title":"Elevated calprotectin levels reveal bowel inflammation in spondyloarthritis","volume":"75","author":"Cypers","year":"2016","journal-title":"Ann Rheum Dis"},{"key":"B15","doi-asserted-by":"publisher","first-page":"498","DOI":"10.3899\/jrheum.161216","article-title":"Detection of Crohn disease in patients with spondyloarthropathy: the SpACE Capsule Study","volume":"45","author":"Kopylov","year":"2018","journal-title":"J Rheumatol."},{"key":"B16","doi-asserted-by":"publisher","first-page":"R304","DOI":"10.1186\/s13075-016-1200-1","article-title":"Serum biomarkers and changes in clinical\/MRI evidence of golimumab-treated patients with ankylosing spondylitis: results of the randomized, placebo-controlled GO-RAISE study","volume":"18","author":"Inman","year":"2016","journal-title":"Arthritis Res Ther."},{"key":"B17","doi-asserted-by":"publisher","first-page":"R127","DOI":"10.1186\/ar3857","article-title":"Association of cytokine and matrix metalloproteinase profiles with disease activity and function in ankylosing spondylitis","volume":"14","author":"Mattey","year":"2012","journal-title":"Arthritis Res Ther."},{"key":"B18","doi-asserted-by":"publisher","DOI":"10.1007\/s00198-018-4721-4","article-title":"Hepatocyte growth factor is a potential biomarker for osteoproliferation and osteoporosis in ankylosing spondylitis","author":"Torres","year":"2018","journal-title":"Osteoporos Int."},{"key":"B19","doi-asserted-by":"publisher","first-page":"e000648","DOI":"10.1136\/rmdopen-2018-000648","article-title":"Is radiographic progression in radiographic axial spondyloarthritis related to matrix metalloproteinase degradation of extracellular matrix?","volume":"4","author":"Siebuhr","year":"2018","journal-title":"RMD Open"},{"key":"B20","doi-asserted-by":"publisher","first-page":"5027","DOI":"10.3892\/etm.2017.5155","article-title":"Correlation of the expression of miR-146a in peripheral blood mononuclear cells of patients with ankylosing spondylitis and inflammatory factors","volume":"14","author":"Wei","year":"2017","journal-title":"Exp Ther Med"},{"key":"B21","doi-asserted-by":"publisher","first-page":"1369","DOI":"10.1136\/ard.2010.145995","article-title":"Rates and predictors of radiographic sacroiliitis progression over 2 years in patients with axial spondyloarthritis","volume":"70","author":"Poddubnyy","year":"2011","journal-title":"Ann Rheum Dis."},{"key":"B22","doi-asserted-by":"publisher","first-page":"2114","DOI":"10.1136\/annrheumdis-2016-209209","article-title":"High disease activity according to the Ankylosing Spondylitis Disease Activity Score is associated with accelerated radiographic spinal progression in patients with early axial spondyloarthritis: results from the GErman SPondyloarthritis Inception Cohort","volume":"75","author":"Poddubnyy","year":"2016","journal-title":"Ann Rheum Dis."},{"key":"B23","doi-asserted-by":"publisher","first-page":"2645","DOI":"10.1002\/art.38070","article-title":"The impact of tumor necrosis factor alpha inhibitors on radiographic progression in ankylosing spondylitis","volume":"65","author":"Haroon","year":"2013","journal-title":"Arthritis Rheum."},{"key":"B24","doi-asserted-by":"publisher","first-page":"1623","DOI":"10.1136\/annrheumdis-2012-201370","article-title":"Continuous NSAID use reverts the effects of inflammation on radiographic progression in patients with ankylosing spondylitis","volume":"71","author":"Kroon","year":"2012","journal-title":"Ann Rheum Dis."},{"key":"B25","doi-asserted-by":"publisher","first-page":"1438","DOI":"10.1136\/annrheumdis-2015-207897","article-title":"Effect of continuous versus on-demand treatment of ankylosing spondylitis with diclofenac over 2 years on radiographic progression of the spine: results from a randomised multicentre trial (ENRADAS)","volume":"75","author":"Sieper","year":"2016","journal-title":"Ann Rheum Dis"},{"key":"B26","doi-asserted-by":"publisher","first-page":"1746","DOI":"10.1136\/annrheumdis-2014-205506","article-title":"Calprotectin serum level is an independent marker for radiographic spinal progression in axial spondyloarthritis","volume":"73","author":"Turina","year":"2014","journal-title":"Ann Rheum Dis."},{"key":"B27","doi-asserted-by":"publisher","first-page":"1796","DOI":"10.1002\/art.40175","article-title":"Macrophage migration inhibitory factor induces inflammation and predicts spinal Progression in ankylosing spondylitis","volume":"69","author":"Ranganathan","year":"2017","journal-title":"Arthritis Rheumatol."},{"key":"B28","doi-asserted-by":"publisher","first-page":"678","DOI":"10.1002\/art.38968","article-title":"Serum adipokine levels in patients with ankylosing spondylitis and their relationship to clinical parameters and radiographic spinal progression","volume":"67","author":"Syrbe","year":"2015","journal-title":"Arthritis Rheumatol."},{"key":"B29","doi-asserted-by":"publisher","first-page":"1467","DOI":"10.1084\/jem.20030286","article-title":"MIF signal transduction initiated by binding to CD74","volume":"197","author":"Leng","year":"2003","journal-title":"J Exp Med."},{"key":"B30","doi-asserted-by":"publisher","first-page":"142","DOI":"10.1186\/s13059-017-1271-6","article-title":"Quantitative metagenomics reveals unique gut microbiome biomarkers in ankylosing spondylitis","volume":"18","author":"Wen","year":"2017","journal-title":"Genome Biol."},{"key":"B31","doi-asserted-by":"publisher","first-page":"826316","DOI":"10.1155\/2015\/826316","article-title":"Identification of potential transcriptomic markers in developing ankylosing spondylitis: a meta-analysis of gene expression profiles","volume":"2015","author":"Fang","year":"2015","journal-title":"Biomed Res Int"},{"key":"B32","doi-asserted-by":"publisher","first-page":"735","DOI":"10.1097\/BRS.0000000000001339","article-title":"Identification of serum miR-146a and miR-155 as novel noninvasive complementary biomarkers for ankylosing spondylitis","volume":"41","author":"Qian","year":"2016","journal-title":"Spine"},{"key":"B33","doi-asserted-by":"publisher","first-page":"620","DOI":"10.1136\/annrheumdis-2016-210175","article-title":"miR-10b-5p is a novel Th17 regulator present in Th17 cells from ankylosing spondylitis","volume":"76","author":"Chen","year":"2017","journal-title":"Ann Rheum Dis"},{"key":"B34","doi-asserted-by":"publisher","first-page":"113543","DOI":"10.18632\/oncotarget.22708","article-title":"Differentially expressed mRNAs, lncRNAs, and miRNAs with associated coexpression and ceRNA networks in ankylosing spondylitis","volume":"8","author":"Zhang","year":"2017","journal-title":"Oncotarget"},{"key":"B35","doi-asserted-by":"publisher","first-page":"604","DOI":"10.1002\/bmc.3321","article-title":"Serum fatty acid profiles and potential biomarkers of ankylosing spondylitis determined by gas chromatography-mass spectrometry and multivariate statistical analysis","volume":"29","author":"Chen","year":"2015","journal-title":"Biomed Chromatogr."},{"key":"B36","doi-asserted-by":"publisher","first-page":"R244","DOI":"10.1186\/s13075-016-1139-2","article-title":"Plasma, urine and ligament tissue metabolite profiling reveals potential biomarkers of ankylosing spondylitis using NMR-based metabolic profiles","volume":"18","author":"Wang","year":"2016","journal-title":"Arthritis Res Ther."},{"key":"B37","doi-asserted-by":"publisher","first-page":"859","DOI":"10.1136\/gut.2008.170019","article-title":"Monitoring disease activity by stool analyses: from occult blood to molecular markers of intestinal inflammation and damage","volume":"58","author":"Foell","year":"2009","journal-title":"Gut"},{"key":"B38","doi-asserted-by":"publisher","first-page":"56","DOI":"10.1016\/j.dld.2008.05.008","article-title":"Questions and answers on the role of faecal calprotectin as a biological marker in inflammatory bowel disease","volume":"41","author":"Gisbert","year":"2009","journal-title":"Dig Liver Dis"},{"key":"B39","doi-asserted-by":"publisher","first-page":"879","DOI":"10.1007\/s00535-009-0102-2","article-title":"Present status and strategy of NSAIDs-induced small bowel injury","volume":"44","author":"Higuchi","year":"2009","journal-title":"J Gastroenterol"},{"key":"B40","doi-asserted-by":"publisher","first-page":"972","DOI":"10.1002\/art.37843","article-title":"Circulating citrullinated vimentin fragments reflect disease burden in ankylosing spondylitis and have prognostic capacity for radiographic progression","volume":"65","author":"Bay-Jensen","year":"2013","journal-title":"Arthritis Rheumatol"},{"key":"B41","doi-asserted-by":"publisher","first-page":"191","DOI":"10.1186\/s13075-018-1692-y","article-title":"An explorative study on deep profiling of peripheral leukocytes to identify predictors for responsiveness to anti-tumour necrosis factor alpha therapies in ankylosing spondylitis: natural killer cells in focus","volume":"20","author":"Schulte-Wrede","year":"2018","journal-title":"Arthritis Res Ther."},{"key":"B42","doi-asserted-by":"publisher","first-page":"237","DOI":"10.1016\/S8756-3282(98)00183-5","article-title":"Biochemical markers can predict the response in bone mass during alendronate treatment in early postmenopausal women. Alendronate Osteoporosis Prevention Study Group.","volume":"24","author":"Ravn","year":"1999","journal-title":"Bone"},{"key":"B43","doi-asserted-by":"publisher","first-page":"1531","DOI":"10.1002\/jbmr.5650111021","article-title":"Markers of bone resorption predict hip fracture in elderly women: the EPIDOS Prospective Study","volume":"11","author":"Garnero","year":"1996","journal-title":"J Bone Miner Res."},{"key":"B44","doi-asserted-by":"publisher","first-page":"2137","DOI":"10.1136\/annrheumdis-2013-203824","article-title":"Elevated serum level of the vascular endothelial growth factor predicts radiographic spinal progression in patients with axial spondyloarthritis","volume":"73","author":"Poddubnyy","year":"2014","journal-title":"Ann Rheum Dis."},{"key":"B45","doi-asserted-by":"publisher","first-page":"901","DOI":"10.3899\/jrheum.150897","article-title":"Serum vascular endothelial growth factor levels lack predictive value in patients with active ankylosing spondylitis treated with golimumab","volume":"43","author":"Braun","year":"2016","journal-title":"J Rheumatol."},{"key":"B46","doi-asserted-by":"publisher","first-page":"7731","DOI":"10.1038\/s41598-018-25722-z","article-title":"Increase in IL-31 serum levels is associated with reduced structural damage in early axial spondyloarthritis","volume":"8","author":"Rosine","year":"2018","journal-title":"Sci Rep."},{"key":"B47","doi-asserted-by":"publisher","first-page":"1257","DOI":"10.1136\/gut.2006.118679","article-title":"Interleukin 31 mediates MAP kinase and STAT1\/3 activation in intestinal epithelial cells and its expression is upregulated in inflammatory bowel disease","volume":"56","author":"Dambacher","year":"2007","journal-title":"Gut"},{"key":"B48","doi-asserted-by":"publisher","first-page":"543","DOI":"10.2174\/1566524015666150731100012","article-title":"Cytokine expression profile in aqueous humor and sera of patients with acute anterior uveitis","volume":"15","author":"Chen","year":"2015","journal-title":"Curr Mol Med."},{"key":"B49","doi-asserted-by":"publisher","first-page":"60","DOI":"10.1186\/s12865-015-0125-9","article-title":"Increased levels of interleukin 31 (IL-31) in osteoporosis","volume":"16","author":"Ginaldi","year":"2015","journal-title":"BMC Immunol"},{"key":"B50","doi-asserted-by":"publisher","first-page":"140","DOI":"10.1186\/s13075-017-1350-9","article-title":"Serum levels of leptin and high molecular weight adiponectin are inversely associated with radiographic spinal progression in patients with ankylosing spondylitis: results from the ENRADAS trial","volume":"19","author":"Hartl","year":"2017","journal-title":"Arthritis Res Ther."},{"key":"B51","doi-asserted-by":"publisher","first-page":"579","DOI":"10.1111\/cts.12265","article-title":"Quantitative proteomic analysis of peripheral blood mononuclear cells in ankylosing spondylitis by iTRAQ","volume":"8","author":"Cai","year":"2015","journal-title":"Clin Transl Sci."},{"key":"B52","doi-asserted-by":"publisher","first-page":"2481","DOI":"10.1159\/000480211","article-title":"MicroRNA-199a-5p induced autophagy and inhibits the pathogenesis of ankylosing spondylitis by modulating the mTOR signaling via directly targeting Ras homolog enriched in brain (Rheb)","volume":"42","author":"Wang","year":"2017","journal-title":"Cell Physiol Biochem."},{"key":"B53","doi-asserted-by":"publisher","first-page":"74","DOI":"10.1016\/j.yexcr.2016.07.010","article-title":"miR-106b-5p and miR-17-5p suppress osteogenic differentiation by targeting Smad5 and inhibit bone formation","volume":"347","author":"Fang","year":"2016","journal-title":"Exp Cell Res."},{"key":"B54","doi-asserted-by":"publisher","first-page":"3281","DOI":"10.3892\/ol.2017.7714","article-title":"MMP-2 silencing reduces the osteogenic transformation of fibroblasts by inhibiting the activation of the BMP\/Smad pathway in ankylosing spondylitis","volume":"15","author":"Yuan","year":"2018","journal-title":"Oncol Lett."},{"key":"B55","doi-asserted-by":"publisher","first-page":"e15004","DOI":"10.1371\/journal.pone.0015004","article-title":"Aptamer-based multiplexed proteomic technology for biomarker discovery","volume":"5","author":"Gold","year":"2010","journal-title":"PLoS ONE"},{"key":"B56","doi-asserted-by":"publisher","first-page":"769","DOI":"10.1126\/science.aaq1327","article-title":"Co-regulatory networks of human serum proteins link genetics to disease","volume":"361","author":"Emilsson","year":"2018","journal-title":"Science"}],"container-title":["Frontiers in Immunology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/article\/10.3389\/fimmu.2019.00305\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,3,7]],"date-time":"2019-03-07T06:30:18Z","timestamp":1551940218000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/article\/10.3389\/fimmu.2019.00305\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,3,7]]},"references-count":56,"alternative-id":["10.3389\/fimmu.2019.00305"],"URL":"https:\/\/doi.org\/10.3389\/fimmu.2019.00305","relation":{},"ISSN":["1664-3224"],"issn-type":[{"value":"1664-3224","type":"electronic"}],"subject":[],"published":{"date-parts":[[2019,3,7]]},"article-number":"305"}}